Advertisement

KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab for Triple-Negative Breast Cancer
Posted: 02/28/2022 | By: Matthew Stenger

Question 1 of 5

For the pembrolizumab group vs control group in the total population, distant recurrence was the first event-free survival event in:

Choose 1

A
7.7% vs 13.1%
B
3.6% vs 4.4%
C
5.5% vs 7.4%
D
None of the above

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage